NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) announced today that through an innovative collaboration with Onyx Pharmaceuticals, it has launched a new initiative to make carfilzomib available immediately through an expanded access program to eligible patients in the United States with relapsed and refractory multiple myeloma who have no available treatment options.
